QUILT-3.055: A Phase 2b, Single-Arm, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors. DRUGS: N-803 (aka ALT-803) + PD-L1 t-haNK suspension for infusion This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the...